Bench to bedside targeting of FLT3 in acute leukemia.

doi:10.2174/138945010791320782

Back to search

Article

Bench to bedside targeting of FLT3 in acute leukemia.

Current drug targets - 1 Jul 2010

Pratz Keith W, Levis Mark J

Abstract excerpt

FMS-Like-Tyrosine kinase-3 (FLT3) mutations are found in about 30% of cases of acute myeloid leukemia and confer an increased relapse rate and reduced overall survival. Targeting this tyrosine kinase by direction inhibition is the focus of both preclinical and clinical research in AML. Several mo...

Topics

Antineoplastic Combined Chemotherapy Protocols
Biological Assay
Drug Delivery Systems
Drug Resistance, Neoplasm
Drugs, Investigational
Humans
Leukemia, Myeloid, Acute
Mutation
Protein Kinase Inhibitors
Translational Research, Biomedical
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.